1147 / 1816
Anthracyclines
The role of non-anthracycline chemotherapy needs further investigation
in lesser risk cancers
Additional follow up and correlative studies to identify biomarkers of
anthracycline benefit will be crucial for fully determining the utility of
anthracyclines
The use of neoadjuvant chemotherapy for larger cancers with
pathological Complete Remission as a surrogate end point might
identify more patients who do not require more intensive
anthracycline-containing regimens.
19-9-2017